Close Menu

NEW YORK – Aspira Women's Health reported after the close of the market on Thursday that its fourth quarter revenues were up 11 percent year over year.

Separately, the Austin, Texas-based company said it has signed an agreement with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate their microRNA technology combined with Aspira's current technologies in order to develop a highly sensitive and specific high-risk, early detection test for ovarian cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.